BeiGene, Ltd.

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 20/09/2024 am IST			5-day change	1st Jan Change
198.59 ^USD	+0.66%		+1.18%	+10.11%

18/09	JMP Securities Initiates BeiGene at Outperform With $288 Price Target	MT
17/09	BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma After Prior Chemotherapy	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about BeiGene, Ltd.

JMP Securities Initiates BeiGene at Outperform With $288 Price Target	18/09	MT
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma After Prior Chemotherapy	17/09	CI
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	12/09	MT
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	11/09	MT
BeiGene, Ltd. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:00 AM	05/09
BeiGene Grants Share Options, RSUs under Incentive Plan	05/09	MT
BeiGene's H1 Loss Narrows as Revenue Rises	27/08	MT
Sector Update: Health Care Stocks Higher Pre-Bell Monday	26/08	MT
Sector Update: Health Care	26/08	MT
BeiGene Says BGB-16673 Gets FDA Fast Track Status for Lymphocytic Leukemia, Lymphoma	26/08	MT
BeiGene Narrows H1 Loss on Higher Product Sales; Hong Kong Shares Gain 3%	08/08	MT
BeiGene Shrinks Loss in Fiscal Q2 Amid 56% Revenue Boost	07/08	MT
BeiGene' Q2 Net Loss Narrows, Revenue Rises; Shares Gain	07/08	MT
Earnings Flash (BGNE) BEIGENE Posts Q2 Revenue $929.2M	07/08	MT
BeiGene, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07/08	CI
BeiGene Opens Flagship US Biologics Manufacturing Facility in New Jersey	23/07	MT
BeiGene Opens U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World	23/07	CI
BeiGene Appoints CFO	18/07	MT
BeiGene Names Aaron Rosenberg CFO	18/07	MT
BeiGene Names Rosenberg Finance Chief as Wang Departs	18/07	DJ
Beigene, Ltd. Appoints Aaron Rosenberg as the Principal Financial Officer, Effective from July 22, 2024	18/07	CI
BeiGene, Ltd. Announces CFO Changes	18/07	CI
Nomura Adjusts BeiGene Price Target to $266 From $248.41, Maintains Buy Rating	16/07	MT
Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy	16/07	MT
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading	12/07	MT

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Employees

10,000

Sector

Biotechnology & Medical Research

Calendar

07/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company